文献速递神经肿瘤

达克替尼(pan-HER酪氨酸激酶抑制剂)治疗EGFR扩增的复发胶质母细胞瘤患者的II期试验

Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification.
PubMed 文献 · Neuro Oncol · 2017-01-01

这项多中心、两阶段、开放标签II期试验评估达克替尼在EGFR扩增伴或不伴EGFRvIII突变的复发胶质母细胞瘤成人患者中的疗效与安全性,A组(无EGFRvIII突变)30例、B组(有EGFRvIII突变)19例,达克替尼45 mg/天直至疾病进展或不可接受的不良事件。6个月无进展生存率为10.6%(A组13.3%,B组5.9%),中位无进展生存期2.7个月,中位总生存期7.4个月。结论认为达克替尼单药在EGFR扩增的复发胶质母细胞瘤中活性有限。

要点

  • 6个月无进展生存率为10.6%(A组13.3%,B组5.9%),中位无进展生存期2.7个月。
  • 中位总生存期为7.4个月(A组7.8个月,B组6.7个月)。
  • 20例(40.8%)患者发生3-4级药物相关不良事件,腹泻和皮疹最常见。

核心结论

  • 达克替尼在EGFR扩增的复发胶质母细胞瘤中单药活性有限。
  • 本试验中4例有反应患者的详细分子特征可能有助于筛选可从达克替尼获益的患者。

研究设计与样本

  • 多中心、两阶段、开放标签II期试验。
  • 纳入首次复发的成人胶质母细胞瘤患者,要求EGFR基因扩增伴或不伴EGFRvIII突变。
  • A组为EGFR基因扩增不伴EGFRvIII突变,纳入30例;B组为EGFR基因扩增伴EGFRvIII突变,纳入19例。
  • 达克替尼给药剂量为45 mg/天,直至疾病进展或不可接受的不良事件。
  • 主要终点为6个月无进展生存率(PFS6,采用RANO标准)。

主要发现

  • 中位年龄59岁(范围39-81岁),男性占65.3%,ECOG体能状态0/1/2分别占10.2%/65.3%/24.5%。
  • 6个月无进展生存率为10.6%(A组13.3%;B组5.9%),中位无进展生存期为2.7个月(A组2.7个月;B组2.6个月)。
  • 4例患者在6个月时无进展,3例患者在12个月时无进展。
  • 中位总生存期为7.4个月(A组7.8个月;B组6.7个月)。
  • 最佳总体反应包括1例完全缓解和2例部分缓解(4.1%);12例(24.5%)达疾病稳定(A组8例,B组4例)。

局限性

  • 达克替尼在复发胶质母细胞瘤中单药活性有限。
  • 作者认为本试验中4例有反应患者的详细分子特征可用于筛选可能从达克替尼获益的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We conducted a multicenter, 2-stage, open-label, phase II trial to assess the efficacy and safety of dacomitinib in adult patients with recurrent glioblastoma (GB) and epidermal growth factor receptor gene (EGFR) amplification with or without variant III (EGFRvIII) deletion. METHODS: Patients with first recurrence were enrolled in 2 cohorts. Cohort A included patients with EGFR gene amplification without EGFRvIII mutation. Cohort B included patients with EGFR gene amplification and EGFRvIII mutation. Dacomitinib was administered (45 mg/day) until disease progression/unacceptable adverse events (AEs). Primary endpoint was progression-free survival (PFS; RANO criteria) at 6 months (PFS6). RESULTS: Thirty patients in Cohort A and 19 in Cohort B were enrolled. Median age was 59 years (range 39-81), 65.3% were male, and Eastern Cooperative Oncology Group Performance Status 0/1/2 were 10.2%/65.3%/24.5%, respectively. PFS6 was 10.6% (Cohort A: 13.3%; Cohort B: 5.9%) with a median PFS of 2.7 months (Cohort A: 2.7 mo; Cohort B: 2.6 mo). Four patients were progression free at 6 months and 3 patients were so at 12 months. Median overall survival was 7.4 months (Cohort A: 7.8 mo; Cohort B: 6.7 mo). The best overall response included 1 complete response and 2 partial responses (4.1%). Stable disease was observed in 12 patients (24.5%: eight in Cohort A and four in Cohort B). Diarrhea and rash were the most common AEs; 20 (40.8%) patients experienced grade 3-4 drug-related AEs. CONCLUSIONS: Dacomitinib has a limited single-agent activity in recurrent GB with EGFR amplification. The detailed molecular characterization of the 4 patients with response in this trial can be useful to select patients who could benefit from dacomitinib.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Sepúlveda-Sánchez JM, Vaz MÁ, Balañá C, et al. Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification. Neuro Oncol. 2017. PMID: 28575464. doi:10.1093/neuonc/nox105

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。